Clincosm LogoSign in Get a demo

agvhd

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

GVHD, GVHD, Acute-graft-versus-host Disease Trial in Canada, United States (Itolizumab, EQ001 Placebo)

Recruiting
  • Graft Versus Host Disease
  • +4 more
  • Itolizumab
  • EQ001 Placebo
  • Duarte, California
  • +5 more
Jul 5, 2022

aGVHD, Stem Cell Transplant Complications Trial in Beijing (Ruxolitinib, Corticosteroid)

Recruiting
  • aGVHD
  • Stem Cell Transplant Complications
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 23, 2022

aGVHD, cGVHD Trial in Beijing (Rabbit ATG)

Recruiting
  • aGVHD
  • cGVHD
  • Rabbit ATG
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 21, 2022

aGVHD, Stem Cell Transplant Complications Trial in Beijing (Ruxolitinib 10 mg twice a day combined with Corticosteroids,

Completed
  • aGVHD
  • Stem Cell Transplant Complications
  • Ruxolitinib 10 mg twice a day combined with Corticosteroids
  • +3 more
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Dec 12, 2021

Acute-graft-versus-host Disease, aGVHD, GVHD Trial in United States (EQ001, EQ001 Placebo)

Recruiting
  • Acute-graft-versus-host Disease
  • +3 more
  • EQ001
  • EQ001 Placebo
  • Duarte, California
  • +18 more
Oct 1, 2021

Biomarker Study for Prediction of aGVHD

Unknown status
  • aGVHD
    • Shanghai, Shanghai, China
      Blood & Marrow Transplantation Center, RuiJin Hospital
    Aug 2, 2018

    Peripheral Blood Stem Cell Transplantation, aGVHD Trial in Shanghai (VPA)

    Unknown status
    • Peripheral Blood Stem Cell Transplantation
    • aGVHD
    • Shanghai, Shanghai, China
      Blood & Marrow Transplantation Center, RuiJin Hospital
    Jul 29, 2016